dc.identifier.uri |
http://dx.doi.org/10.15488/3625 |
|
dc.identifier.uri |
https://www.repo.uni-hannover.de/handle/123456789/3657 |
|
dc.contributor.author |
Mühlberger, Nikolai
|
|
dc.contributor.author |
Sroczynski, Gaby
|
|
dc.contributor.author |
Esteban, Eva
|
|
dc.contributor.author |
Mittendorf, Thomas
|
|
dc.contributor.author |
Miksad, Rebecca A.
|
|
dc.contributor.author |
Siebert, Uwe
|
|
dc.date.accessioned |
2018-08-23T12:59:40Z |
|
dc.date.available |
2018-08-23T12:59:40Z |
|
dc.date.issued |
2008 |
|
dc.identifier.citation |
Mühlberger, N.; Sroczynski, G.; Esteban, E.; Mittendorf, T.; Miksad, R.A.; Siebert, U.: Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. In: International Journal of Technology Assessment in Health Care 24 (2008), Nr. 2, S. 184-192. DOI: https://doi.org/10.1017/S0266462308080264 |
|
dc.description.abstract |
Objectives: The aim of this study was to summarize the current evidence for the cost-effectiveness of primarily human papillomavirus (HPV) -based cervical cancer screening in settings with already established Papanicolaou test (Pap) programs. Emphasis was placed on the German situation with annual Pap screening. Methods: Medical, economic, and health technology assessment (HTA) databases were systematically searched for cost-effectiveness studies comparing HPV to Pap screening. Study data were extracted, standardized, and summarized in cost-effectiveness plots contrasting HPV strategies to Pap screening with 1-, 2-, 3-, and 5-years interval. For each Pap setting, the likelihood of cost-effective HPV screening was assessed depending on willingness-to-pay. Results: We reviewed twelve decision-analytic cost-effectiveness models. Study results showed wide variation due to methodical heterogeneity. Data synthesis revealed that the cost-effectiveness of HPV screening depends on the interval of the established Pap screening strategy. In comparison with Pap screening every 2 years, only 25 percent of the HPV-based screening strategies were cost-effective. However, in comparison with Pap screening every 1, 3, or 5 years, 83 percent, 55 percent, and 92 percent of HPV screening strategies were cost-effective, respectively. Results for settings with annual Pap screening are based on models assuming 100 percent screening coverage. Conclusions: The introduction of HPV-based screening programs is cost-effective if the screening interval of the established Pap program exceeds 2 years. In settings with biennial Pap screening, introduction of HPV-based screening is unlikely to be cost-effective. Results also suggest cost-effectiveness of HPV-based screening in settings with annual Pap screening; however, this finding should be confirmed under realistic screening adherence assumptions. © 2008 Cambridge University Press. |
eng |
dc.language.iso |
eng |
|
dc.publisher |
Cambridge : Cambridge University Press |
|
dc.relation.ispartofseries |
International Journal of Technology Assessment in Health Care 24 (2008), Nr. 2 |
|
dc.rights |
Es gilt deutsches Urheberrecht. Das Dokument darf zum eigenen Gebrauch kostenfrei genutzt, aber nicht im Internet bereitgestellt oder an Außenstehende weitergegeben werden. Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. |
|
dc.subject |
Cervical cancer |
eng |
dc.subject |
Cost-effectiveness |
eng |
dc.subject |
Health technology assessment |
eng |
dc.subject |
Human papillomavirus |
eng |
dc.subject |
Screening |
eng |
dc.subject |
Cervical cancer |
eng |
dc.subject |
Health technology assessment |
eng |
dc.subject |
Human papillomavirus |
eng |
dc.subject |
Cost effectiveness |
eng |
dc.subject |
Medical problems |
eng |
dc.subject |
Screening |
eng |
dc.subject |
Health care |
eng |
dc.subject |
biomedical technology assessment |
eng |
dc.subject |
cancer screening |
eng |
dc.subject |
cost effectiveness analysis |
eng |
dc.subject |
diagnostic value |
eng |
dc.subject |
female |
eng |
dc.subject |
Germany |
eng |
dc.subject |
health program |
eng |
dc.subject |
human |
eng |
dc.subject |
information processing |
eng |
dc.subject |
intermethod comparison |
eng |
dc.subject |
major clinical study |
eng |
dc.subject |
Papanicolaou test |
eng |
dc.subject |
patient compliance |
eng |
dc.subject |
prospective payment |
eng |
dc.subject |
review |
eng |
dc.subject |
standardization |
eng |
dc.subject |
systematic review |
eng |
dc.subject |
uterine cervix cancer |
eng |
dc.subject |
Wart virus |
eng |
dc.subject |
Cost-Benefit Analysis |
eng |
dc.subject |
Decision Support Techniques |
eng |
dc.subject |
Female |
eng |
dc.subject |
Germany |
eng |
dc.subject |
Humans |
eng |
dc.subject |
Mass Screening |
eng |
dc.subject |
Papillomavirus Infections |
eng |
dc.subject |
Quality-Adjusted Life Years |
eng |
dc.subject |
Sensitivity and Specificity |
eng |
dc.subject |
Technology Assessment, Biomedical |
eng |
dc.subject |
Uterine Cervical Neoplasms |
eng |
dc.subject |
Vaginal Smears |
eng |
dc.subject.ddc |
330 | Wirtschaft
|
ger |
dc.subject.ddc |
610 | Medizin, Gesundheit
|
ger |
dc.title |
Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health |
eng |
dc.type |
Article |
|
dc.type |
Text |
|
dc.relation.issn |
02664623 |
|
dc.relation.doi |
https://doi.org/10.1017/S0266462308080264 |
|
dc.bibliographicCitation.issue |
2 |
|
dc.bibliographicCitation.volume |
24 |
|
dc.bibliographicCitation.firstPage |
184 |
|
dc.bibliographicCitation.lastPage |
192 |
|
dc.description.version |
publishedVersion |
|
tib.accessRights |
frei zug�nglich |
|